New Launch17 Jun 2026, 05:10 pm
Lupin Launches Azilsartan Medoxomil Tablets in US
AI Summary
Lupin Limited has launched Azilsartan Medoxomil Tablets (40mg and 80mg) in the United States, following U.S. FDA approval. This product is bioequivalent to Edarbi® and is indicated for treating hypertension in adults. Lupin is the exclusive first-to-file for this product and is eligible for 180-day generic drug exclusivity. Azilsartan Medoxomil Tablets had estimated annual sales of USD 53.5 million in the U.S. as of April 2026. This launch strengthens Lupin's cardiovascular portfolio in the significant U.S. market.
Key Highlights
- Lupin launches Azilsartan Medoxomil Tablets in the US.
- Product approved by U.S. FDA for hypertension treatment.
- Lupin is exclusive first-to-file, eligible for exclusivity.
- RLD had US sales of $53.5 million (IQVIA MAT April 2026).
Price Impact
More from LUPIN